Stockreport

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Lantern Pharma Inc.  (LTRN) 
PDF Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipelineOrphan designation expands LP-284's potential for an estimate [Read more]